متابعة
James Campbell
James Campbell
Lead Bioinformatician, Head of CRUK Bioinformatics Facility, Institute of Cancer Research
بريد إلكتروني تم التحقق منه على icr.ac.uk
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
Proteome-based plasma biomarkers for Alzheimer's disease‏
A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, ...‏
Brain 129 (11), 3042-3050, 2006‏
5822006
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease‏
M Thambisetty, A Simmons, L Velayudhan, A Hye, J Campbell, Y Zhang, ...‏
Archives of general psychiatry 67 (7), 739-748, 2010‏
4852010
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor‏
LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ...‏
The Journal of pathology 229 (3), 422-429, 2013‏
3762013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity‏
I Bajrami, JR Frankum, A Konde, RE Miller, FL Rehman, R Brough, ...‏
Cancer research 74 (1), 287-297, 2014‏
3672014
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance‏
SJ Pettitt, DB Krastev, I Brandsma, A Dréan, F Song, R Aleksandrov, ...‏
Nature communications 9 (1), 1849, 2018‏
3562018
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A‏
CT Williamson, R Miller, HN Pemberton, SE Jones, J Campbell, A Konde, ...‏
Nature communications 7 (1), 13837, 2016‏
3182016
Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C‏
NH Dryden, LR Broome, F Dudbridge, N Johnson, N Orr, S Schoenfelder, ...‏
Genome research 24 (11), 1854-1868, 2014‏
2722014
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial‏
A Pearson, E Smyth, IS Babina, MT Herrera-Abreu, N Tarazona, C Peckitt, ...‏
Cancer discovery 6 (8), 838-851, 2016‏
2562016
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity‏
SJ Pettitt, FL Rehman, I Bajrami, R Brough, F Wallberg, I Kozarewa, ...‏
PloS one 8 (4), e61520, 2013‏
1852013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study‏
JE Ang, C Gourley, CB Powell, H High, R Shapira-Frommer, ...‏
Clinical Cancer Research 19 (19), 5485-5493, 2013‏
1522013
Plasma biomarkers of brain atrophy in Alzheimer's disease‏
M Thambisetty, A Simmons, A Hye, J Campbell, E Westman, Y Zhang, ...‏
PloS one 6 (12), e28527, 2011‏
1362011
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer‏
MT Herrera-Abreu, A Pearson, J Campbell, SD Shnyder, MA Knowles, ...‏
Cancer discovery 3 (9), 1058-1071, 2013‏
1312013
Large-scale profiling of kinase dependencies in cancer cell lines‏
J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ...‏
Cell reports 14 (10), 2490-2501, 2016‏
1182016
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells‏
J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ...‏
British journal of cancer 117 (1), 113-123, 2017‏
1042017
E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer‏
I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ...‏
Cancer discovery 8 (4), 498-515, 2018‏
1032018
CDK1 is a synthetic lethal target for KRAS mutant tumours‏
S Costa-Cabral, R Brough, A Konde, M Aarts, J Campbell, E Marinari, ...‏
PloS one 11 (2), e0149099, 2016‏
992016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib‏
RE Miller, R Brough, I Bajrami, CT Williamson, S McDade, J Campbell, ...‏
Molecular cancer therapeutics 15 (7), 1472-1484, 2016‏
952016
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer‏
SK Sandhu, A Omlin, L Hylands, S Miranda, LJ Barber, R Riisnaes, ...‏
Annals of oncology 24 (5), 1416-1418, 2013‏
902013
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals‏
M Thambisetty, R Tripaldi, J Riddoch-Contreras, A Hye, Y An, J Campbell, ...‏
Journal of Alzheimer's Disease 22 (4), 1099-1109, 2010‏
902010
Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease‏
A Güntert, J Campbell, M Saleem, DP O'Brien, AJ Thompson, HL Byers, ...‏
Journal of Alzheimer's Disease 21 (2), 585-596, 2010‏
882010
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20